
Catalent, Pure MHC Partner
Pure MHC and Catalent sign an agreement to develop RL21A using Catalent's GPEx technology.
Pure MHC, a provider of MHC-based diagnostics and therapeutics, and
Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.